Anaconda Biomed closes $56 million round led by Omega Funds, with COFIDES's FOCO joining

The story so far, in brief; the legwork, and the full article, stay with the original outlet.

Anaconda Biomed, which makes catheters for removing clots in stroke patients, has closed a $56 million round. Omega Funds led it. The newcomer is FOCO, Spain's co-investment fund, which COFIDES manages. Asabys (through Sabadell Asabys I), Ysios Capital and CDTI (through SICC Innvierte) all came back for more.

The money goes to product development and clinical work, chiefly finishing ATHENA, a randomized pivotal IDE trial of 327 patients testing the safety and performance of the ANA Funnel Catheter. The device combines suction with stopping and reversing blood flow, so the clot is caught whole instead of breaking into fragments that travel on. In the United States it is still an investigational device. The ANA5 version already carries a CE mark, and the company builds its products in its own plant on the edge of Barcelona.

Chief executive Trent Reutiman said the round gives the company "the required resources to complete the clinical and regulatory requirements," which is, in medical devices, most of the job.